Is AstraZeneca PLC (AZN.L) a good stock to buy?

Olyth's institutional analysis of AZN.L reveals an Altman Z-Score of 3.93 and a Piotroski F-Score of 8/9. These metrics, combined with its 5-year revenue trend ($58.74B most recent), help investors decide if AZN.L fits their risk profile.

What is the current P/E ratio for AZN.L?

As of the latest trading session, AstraZeneca PLC (AZN.L) has a trailing P/E ratio of 29.98.

Who is the CEO of AstraZeneca PLC?

The current Chief Executive Officer of AstraZeneca PLC is Pascal Claude Roland Soriot.

What was AZN.L's revenue for the last 5 years?

According to its latest income statements, AstraZeneca PLC reported annual revenues of $58.74B (2025), $52.94B (2024), $46.58B (2023), $44.25B (2022), $37.11B (2021) respectively.

Does AZN.L pay a dividend?

AstraZeneca PLC currently pays a dividend to its shareholders, with a trailing dividend yield of 1.58%.

How much debt and cash flow does AZN.L have?

In its latest reporting period, AstraZeneca PLC generated $8.67B in Free Cash Flow against a total debt load of $29.62B.

What is the Price-to-Book (P/B) ratio of AstraZeneca PLC?

The Price-to-Book (P/B) ratio for AstraZeneca PLC (AZN.L) is currently 6.39.

What is the Price-to-Sales (P/S) ratio of AZN.L?

Based on trailing twelve-month data, AstraZeneca PLC (AZN.L) trades at a Price-to-Sales (P/S) ratio of 5.22.

What is AstraZeneca PLC's Return on Equity (ROE)?

AstraZeneca PLC (AZN.L) has a Return on Equity (ROE) of 23.00%, representing its profitability relative to shareholder equity.

AZN.L

AstraZeneca PLC · Healthcare

14,958.00

2.34%(-358.00)

Last Updated: — ET

52W L: $9573.5052W H: $15732.00

$14906.00

CHG+805.56 (+5.71%)

H$15436.00

L$13478.00

VOL24M

AZN.L (1h)

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

94,300

IPO Date

1993-05-21

Beta

0.28

Websitewww.astrazeneca.com↗

AZN.L

AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug

New Era Energy & Digital announces planned joint venture for West Texas data center

Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging

Graphene Manufacturing Group receives industry certification and quality audit approval

AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials

AstraZeneca (LON:AZN) Share Price Passes Above 200 Day Moving Average – What’s Next?